Complement activation is involved in biological responses to leukocyte adsorptive apheresis

Digestive Diseases and Sciences

Volumn 51, Issue 5, 2006, Pages 934-941

  Nishise, Shoichi ^a   Takeda, Yuji ^b   Takeda, Hiroaki ^a   Ishihama, Katsuyoshi ^a   Fukui, Tadahisa ^a   Kawata, Sumio ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

Author keywords

Cellulose acetate beads; Complement activation; Granulocytes; Interleukin 1 receptor antagonist; Ulcerative colitis

Indexed keywords

CELLULOSE ACETATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; HEPARIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NAFAMSTAT MESILATE;

ADSORPTION; ADULT; ANTICOAGULATION; ARTICLE; BLOOD; CASE REPORT; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEVICE; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; LEUKAPHERESIS; LEUKOCYTE ADSORPTIVE APHERESIS; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADSORPTION; ADULT; AGED; CELLULOSE; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; FEMALE; GRANULOCYTES; GUANIDINES; HEPARIN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LEUKAPHERESIS; MALE; MICROSPHERES; MIDDLE AGED; SIALOGLYCOPROTEINS;

EID: 33745839687     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-9050-8     Document Type: Article

References (37)

1. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 16:1-9
2. Hay FC, Nineham LJ, Perumal R, Roitt IM (1979) Intra-articular and circulating immune complexes and antiglobulins (IgG and IgM) in rheumatoid arthritis; correlation with clinical features. Ann Rheum Dis 38:1-7
3. Edwards SW, Hallett MB (1997) Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18:320-324
4. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205
5. Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, Kasukawa R (1997) Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989-994
6. Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T (2002) Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47:2349-2353
7. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Aral H, Furuta T, Sugimoto K, Bjarnason I (2003) Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 1:28-35
8. Takeda Y, Hiraishi K, Takeda H, Shiobara N, Shibusawa H, Saniabadi AR, Adachi M, Kawata S (2003) Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumour necrosis factor-α or interleukin-1α in human peripheral blood. Inflamm Res 52:287-290
9. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Adachi T, Shima C, Bjarnason I, Lofberg R (2003) Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48-59
10. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K (2004) Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm Res 53:277-283
11. Arend WP, Malyak M, Guthridge CJ, Gabay C (1998) Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16:27-55
12. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H (2003) Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 307:146-151
13. Hoenich NA, Woffindin C, Matthews JN, Goldfinch ME, Turnbull J (1994) Clinical comparison of high-flux cellulose acetate and synthetic membranes. Nephrol Dial Transplant 9:60-66
14. Matata BM, Yin HQ, Courtney JM, Gaylor JD, Lamba NM, Lowe GD, Suzuki K, Kimura H, Izumi K, Klinkmann H (1996) In vitro blood compatibility evaluation of hollow fibre membrane using a controlled flow system: a comparative study. Int J Artif Organs 19:582-589
15. Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H, Boxer LA, Jacob HS, Hammerschmidt DE (1984) Cellulose acetate hemodialysis membranes are better tolerated than Cuprophan. A difference in complement and neutrophil activation. Contrib Nephrol 37:78-82
16. Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate earner-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7:334-340
17. Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S, Haase I, Lippert U, Zuberbier T (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863-2870
18. Stove S, Welte T, Wagner TOF, Kola A, Klos A, Bautsch W, Kohl J (1996) Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin Diagn Lab Immunol 3:175-183
19. Bjork J, Hugli TE, Smedegard G (1985) Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134:1115-1119
20. Vogt W (1986) Anaphylatoxins: possible roles in disease. Complement 3:177-188
21. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arth Rheum 29:1085-1089
22. Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD (2003) The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 198:913-923
23. Rousseau Y, Haeffner-Cavaillon N, Poignet JL, Meyrier A, Carreno MP (2000) In vivo intracellular cytokine production by leukocytes during haemodialysis. Cytokine 12:506-517
24. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S, Fujita M (1984) Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35:203-227
25. Ikari N, Sakai Y, Hitomi Y, Fujii S (1983) New synthetic inhibitor to the alternative complement pathway. Immunology 49:685-691
26. Beijering RJ, ten Cate H, Nurmohamed MT, ten Cate JW (1997) Anticoagulants and extracorporeal circuits. Semin Thromb Hemost 23:225-233
27. Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y (2003) Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 59:458-162
28. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334-1341
29. Pfeifer PH, Kawahara MS, Hugli TE (1999) Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 45:1190-1199
30. Ezekowitz RAB, Hoffmann JA (1998) Innate immunity. Curr Opin Immunol 10:9-11
31. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW (1980) Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA 77:5764-5768
32. Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701-2705
33. Kolb WP, Morrow PR, Tamerius JD (1989) Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6:175-204
34. Volanakis JE (1990) Participation of C3 and its ligands in complement activation. Curr Top Microbiol Immunol 153:1-21
35. Ueda M, Deguchi M, Takemura S, Kasamatsu Y, Yanagida K, Fukuda W, Okamoto M, Onodera H, Sugino S, Kondo M (1991) The relationship between complement C3 receptors (CR1, CR3) on polymorphonuclear leukocytes and complement fragments during hemodialysis. Nippon Jinzo Gakkai Shi 33:679-684 (in Japanese with English abstract)
36. Webster RO, Larsen GL, Henson PM (1982) In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest 70:1177-1183
37. Nakae H, Tajimi K (2003) Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial 7:483-485